Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C

Open access
Dienstag, Jules L., Ghany, Marc G., Morgan, Timothy R., Di Bisceglie, Adrian M., Bonkovsky, Herbert L., Kim, Hae-Young, Seeff, Leonard B., Szabo, Gyongyi, Wright, Elizabeth C., Sterling, Richard K., Everson, Gregory T., Lindsay, Karen L., Lee, William M., Lok, Anna S., Morishima, Chihiro, Stoddard, Anne M., Everhart, James E.·2011·Hepatology

Abstract

The incidence of liver disease progression among subjects with histologically advanced but compensated chronic hepatitis C is incomplete. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial was a randomized study of 3.5 years of maintenance peginterferon treatment on liver disease progression among patients who had not cleared virus on peginterferon and ribavirin therapy. Patients were followed subsequently off therapy. Because maintenance peginterferon treatment did not alter liver disease progression, we analyzed treated and control patients together. Among 1,050 subjects (60% advanced fibrosis, 40% cirrhosis), we determined the rate of progression to cirrhosis over 4 years and of clinical outcomes over 8 years. Among patients with fibrosis, the incidence of cirrhosis was 9.9% per year. Six hundred seventy-nine clinical outcomes occurred among 329 subjects. Initial clinical outcomes occurred more frequently among subjects with cirrhosis (7.5% per year) than subjects with fibrosis (3.3% per year) ( P < 0.0001). Child-Turcotte-Pugh (CTP) score ≥7 was the most common first outcome, followed by hepatocellular carcinoma. Following occurrence of a CTP score ≥7, the rate of subsequent events increased to 12.9% per year, including a death rate of 10% per year. Age and sex did not influence outcome rates. Baseline platelet count was a strong predictor of all clinical outcomes. During the 8 years of follow-up, death or liver transplantation occurred among 12.2% of patients with advanced fibrosis and 31.5% of those with cirrhosis. Conclusion: Among patients with advanced hepatitis C who failed peginterferon and ribavirin therapy, the rate of liver-related outcomes, including death and liver transplantation, is high, especially once the CTP score reaches at least 7. (Hepatology 2011)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.24370

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 165

Metadata

Authors
Dienstag, J. L., Ghany, M. G., Morgan, T. R., Di Bisceglie, A. M., Bonkovsky, H. L., Kim, H.-Y., Seeff, L. B., Szabo, G., Wright, E. C., Sterling, R. K., Everson, G. T., Lindsay, K. L., Lee, W. M., Lok, A. S., Morishima, C., Stoddard, A. M., & Everhart, J. E.
Venue
Hepatology
Published
2011-08
Volume
54
Issue
2
Pages
396-405
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2143456878
Cited by
165
References
1
FWCI
7.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. https://app.cochat.ai/papers/10.1002/hep.24370
The paper
Dienstag, J. L., Ghany, M. G., Morgan, T. R., Di Bisceglie, A. M., Bonkovsky, H. L., Kim, H.-Y., Seeff, L. B., Szabo, G., Wright, E. C., Sterling, R. K., Everson, G. T., Lindsay, K. L., Lee, W. M., Lok, A. S., Morishima, C., Stoddard, A. M., & Everhart, J. E. (2011). A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. https://doi.org/10.1002/hep.24370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.